Systemic Delivery of aTransgene in Intact Animals by a Retroviral Vector

Essential hypertension is a chronic cardiovascular disease that effects over 50 million people in the United States. It is a complex pathophysiological state that is primarily characterized by a sustained elevation in blood pressure (BP). If untreated, this chronically elevated BP can affect major target organs of the body including the heart, kidney, brain, and vascular system. As a consequence of the sustained high BP, there is an increased risk of mortality and morbidity that is characterized by myocardial infarction, congestive heart failure, stroke, end-stage renal failure, and peripheral vascular disease (1 –3 ). Because hypertension is basically an asymptomatic disease, it confounds effective treatment and makes compliance a major issue in the treatment of this disease. Pharmacological agents currently utilized have to be administered daily in an attempt to control BP, and there are no agents available to cure essential hypertension. Thus, more effective therapeutic intervention is required in order to have a significant impact in alleviating this chronic disease and its lethal cardiovascular sequel.